Refine by
Hemodialysis System Articles & Analysis
24 news found
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a paper featured on the cover of the June 2022 issue of the Journal of Vascular Surgery (JVS) which reports on the use the Surfacer System to perform an Inside-Out® procedure to obtain ...
“The Surfacer Inside-out system represents a new approach to restore right-sided central venous access in chronic thoracic venous occlusion by the inside-out recanalization technique” stated Dr. ...
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
The Surfacer System received U.S. FDA De Novo clearance in February 2020. The Centers for Medicare and Medicaid Services (CMS) established a unique Healthcare Common Procedure Coding System (HCPCS) code for procedure associated with the use of the device (C9780) and assigned the procedure to a New Technology APC (1534) effective October 1, 2021 which has a ...
Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo® Hemodialysis System, enabling full production in North America. The Tablo cartridge is a single-use disposable that works in concert with the console to deliver dialysis treatment. ...
Recent Highlights Recorded net revenue of $28.2 million in the fourth quarter of 2021, a 63.2% increase compared to $17.2 million in the fourth quarter of 2020, and $102.6 million for the full year of 2021, representing an increase of 105.5% compared to $49.9 million for 2020 Achieved gross margin for the fourth quarter of 2021 of 11.8%, compared to 2.4% in the fourth quarter of 2020 Signed ...
Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date. The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. ...
“We report on a patient with a history of multiple central venous catheters which resulted in the development of venous occlusion and the need for the placement of their catheter in a femoral vein. Using the Surfacer System, we were able to cross the patient’s central venous occlusion and obtain central venous access which facilitated the placement of a ...
Specifically designed to simplify dialysis treatment for patients and providers, the Tablo® Hemodialysis System is a first-of-its-kind enterprise solution that is approved for use across the entire continuum of care — from hospital to home. ...
“The ability to utilize the Surfacer System to help facilitate the placement of the HeRO graft as a means of permanent arteriovenous (AV) access and avoid the placement of a femoral catheter reinforces the clinical value the device offers to patients on hemodialysis therapy.” About the Surfacer Inside-Out Access Catheter System The ...
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system), is proud to sponsor a new photography exhibition Survivors: Life Unfiltered, running from 26 October to 7 November 2021, at the OXO Gallery in London. This exhibition was created by award winning ...
Quanta Dialysis Technologies Ltd (“Quanta” of the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, announced today the results of the UK Dialysis Patient Experience Survey, showing the wide variance in care experienced by UK dialysis patients, as well as challenges faced in assessing self-care and ...
On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...
CloudCath, developer of a remote monitoring and predictive analytics platform for catheter-based treatments, today announced a collaboration with American Renal Associates (ARA), a leading provider of outpatient dialysis services. In a U.S.- based, pre-market clinical study, ARA will evaluate the use of CloudCath’s System by peritoneal dialysis (PD) patients. PD is a method of dialysis ...
The use of the Surfacer System to gain central venous access and enable the placement of transvenous cardiac leads combined with the demonstrated adoption of our technology for use in patients requiring central venous catheters for hemodialysis and other therapies represent extremely large market opportunities for the use of our device.” About the ...
The objective of the SAVE Registry was to report Surfacer Inside-Out® Access Catheter System device performance and safety information for patients with thoracic central venous obstruction (TCVO) requiring central venous access. ...
Joseph Hospital in Orange, California, the principal investigator for the SAVE-US study and lead author for the publication reporting these results. “The Surfacer System provides a potentially life-saving approach for patients on hemodialysis and other therapies where placement of central venous catheters is required for ...
The Ellipsys® Vascular Access System enables patients with kidney failure to start dialysis treatment sooner with fewer procedures, complications and interventions compared to surgery, according to several leading physicians who spoke at the recent meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN). ...
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. Invizius is ...